Novel PAH Drug Relieves Pain Linked to Remodulin Treatment
SteadyMed, a pharmaceutical company whose focus is the development of products to treat orphan diseases with unmet clinical needs, has announced promising results from an animal study evaluating the efficacy of its lead drug product Trevyent® in the reduction of the pain associated with the use of United Therapeutics’ Remodulin® to treat pulmonary…